Candida glabrata candidemia: An emerging threat in critically ill patients
- PMID: 25810610
- PMCID: PMC4366913
- DOI: 10.4103/0972-5229.152757
Candida glabrata candidemia: An emerging threat in critically ill patients
Abstract
Background: Candidemia is an important nosocomial blood stream infection in critically ill patients. Although several studies have addressed candidemia, very few have reviewed the impact of Candida glabrata candidemia in Intensive Care Unit (ICU) patients.
Materials and methods: The medical records of ICU patients between 2006 and 2010 were reviewed retrospectively. The epidemiology, clinical features and mortality related risk factors among our adult ICU patients were seen.
Results: Among 144 episodes of candidemia, C. glabrata (n = 26; 18.05%) was the third most common species isolated. The incidence of C. glabrata candidemia was 0.21/1000 ICU admissions. The most common risk factors were prior exposure to broad spectrum antibiotics (100%), central venous catheter (100%), mechanical ventilation (76.9%), diabetes mellitus (50%), age >65 years (46.15%). Urine (23%) was the most common source of C. glabrata candidemia. Overall in hospital 30 days mortality rate due to C. glabrata fungemia was 53.8%. Patients who were treated with fluconazole showed better outcome than patients treated with amphotericin B. Renal failure requiring hemodialysis was the significantly associated with mortality in our study.
Conclusion: Candida glabrata was the 3(rd) most common Candida causing candidemia in our ICUs with a incidence of 0.21/1000 ICU admissions. The outcome of ICU acquired C. glabrata candidemia was poor with 30 days mortality rate of 53.8%. Renal failure requiring hemodialysis was the only risk factor associated with mortality. Further studies are required to identify the other risk factors associated with mortality in C. glabrata candidemia.
Keywords: Candida glabrata candidemia; mortality; risk factors.
Conflict of interest statement
Figures
Similar articles
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60. doi: 10.1128/AAC.49.11.4555-4560.2005. Antimicrob Agents Chemother. 2005. PMID: 16251295 Free PMC article.
-
Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil.Med Mycol. 2013 Apr;51(3):225-30. doi: 10.3109/13693786.2012.708107. Epub 2012 Aug 27. Med Mycol. 2013. PMID: 22920712
-
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.Intensive Care Med. 1997 Jan;23(1):23-30. doi: 10.1007/s001340050286. Intensive Care Med. 1997. PMID: 9037636 Clinical Trial.
-
Epidemiology of candidemia in intensive care units.Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S87-91. doi: 10.1016/S0924-8579(08)70006-2. Int J Antimicrob Agents. 2008. PMID: 19013346 Review.
Cited by
-
Fun(gi)omics: Advanced and Diverse Technologies to Explore Emerging Fungal Pathogens and Define Mechanisms of Antifungal Resistance.mBio. 2020 Oct 6;11(5):e01020-20. doi: 10.1128/mBio.01020-20. mBio. 2020. PMID: 33024032 Free PMC article. Review.
-
Candida Non-albicans and Non-auris Causing Invasive Candidiasis in a Fourth-Level Hospital in Colombia: Epidemiology, Antifungal Susceptibility, and Genetic Diversity.J Fungi (Basel). 2024 Apr 30;10(5):326. doi: 10.3390/jof10050326. J Fungi (Basel). 2024. PMID: 38786681 Free PMC article.
-
Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance.mSphere. 2025 Jul 29;10(7):e0027025. doi: 10.1128/msphere.00270-25. Epub 2025 Jul 7. mSphere. 2025. PMID: 40622137 Free PMC article.
-
Frequency and co-colonization of vancomycin-resistant Enterococci and Candida in ICU-hospitalized children.New Microbes New Infect. 2021 Apr 14;41:100881. doi: 10.1016/j.nmni.2021.100881. eCollection 2021 May. New Microbes New Infect. 2021. PMID: 34026230 Free PMC article.
-
Etoposide and Camptothecin Reduce Growth, Viability, the Generation of Petite Mutants, and Recognize the Active Site of DNA Topoisomerase I and II Enzymes in Candida glabrata.Indian J Microbiol. 2021 Sep;61(3):306-314. doi: 10.1007/s12088-021-00942-6. Epub 2021 May 5. Indian J Microbiol. 2021. PMID: 34294997 Free PMC article.
References
-
- Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17. - PubMed
-
- Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702. - PubMed
-
- Cheng YR, Lin LC, Young TG, Liu CE, Chen CH, Tsay RW. Risk factors for candidemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infect. 2006;39:155–61. - PubMed
-
- Chen TC, Chen YH, Tsai JJ, Peng CF, Lu PL, Chang K, et al. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan. J Microbiol Immunol Infect. 2005;38:200–10. - PubMed
-
- Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc. 1996;95:19–28. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous